- Home
- RRGB vs CRDL Comparison
RRGB vs CRDL Comparison
Compare RRGB & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RRGB
- CRDL
- Stock Information
- Founded
- RRGB 1969
- CRDL 2017
- Country
- RRGB United States
- CRDL Canada
- Employees
- RRGB N/A
- CRDL N/A
- Industry
- RRGB Restaurants
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RRGB Consumer Discretionary
- CRDL Health Care
- Exchange
- RRGB Nasdaq
- CRDL Nasdaq
- Market Cap
- RRGB 91.6M
- CRDL 102.0M
- IPO Year
- RRGB 2002
- CRDL N/A
- Fundamental
- Price
- RRGB $2.72
- CRDL $1.01
- Analyst Decision
- RRGB Strong Buy
- CRDL Strong Buy
- Analyst Count
- RRGB 4
- CRDL 3
- Target Price
- RRGB $11.88
- CRDL $9.00
- AVG Volume (30 Days)
- RRGB 274.5K
- CRDL 221.7K
- Earning Date
- RRGB 05-28-2025
- CRDL 05-13-2025
- Dividend Yield
- RRGB N/A
- CRDL N/A
- EPS Growth
- RRGB N/A
- CRDL N/A
- EPS
- RRGB N/A
- CRDL N/A
- Revenue
- RRGB $1,248,560,000.00
- CRDL N/A
- Revenue This Year
- RRGB $0.60
- CRDL N/A
- Revenue Next Year
- RRGB N/A
- CRDL N/A
- P/E Ratio
- RRGB N/A
- CRDL N/A
- Revenue Growth
- RRGB N/A
- CRDL N/A
- 52 Week Low
- RRGB $2.60
- CRDL $0.77
- 52 Week High
- RRGB $9.20
- CRDL $3.12
- Technical
- Relative Strength Index (RSI)
- RRGB 22.02
- CRDL 49.79
- Support Level
- RRGB $2.60
- CRDL $0.77
- Resistance Level
- RRGB $3.15
- CRDL $1.10
- Average True Range (ATR)
- RRGB 0.25
- CRDL 0.10
- MACD
- RRGB -0.02
- CRDL 0.02
- Stochastic Oscillator
- RRGB 10.71
- CRDL 72.64
About RRGB Red Robin Gourmet Burgers Inc.
Red Robin Gourmet Burgers Inc is a restaurant operator. The company develops, operates, and franchises casual-dining restaurants and fast-casual restaurants in North America. Its brands are Red Robin, Red Robin Gourmet Burgers, Red Robin America's Gourmet Burgers and Spirits, Red Robin Burger Works, YUMMM, Red Robin Gourmet Burgers and Brews, and Red Robin Royalty names and logos. The company's revenue consists of sales from restaurant operations, gift card breakage, franchise royalties and fees, and other miscellaneous revenue.
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.